Psoriasis News

Individuals with moderate to severe psoriasis experience work absenteeism more than those with a mild form of the disease, according to a study.

Guselkumab can effectively and safely treat patients with psoriasis for up to 2 years, according to a study.

Calcipotriol/betamethasone dipropionate, or CAL/BDP, combination cream vs. foam had higher satisfaction ratings among patients with psoriasis, suggesting the cream formulation may increase adherence, according to a study.

Artax Biopharma has recruited all 30 patients to a phase 2a clinical trial of AX-158, its investigative Nck modulator for autoimmune diseases, the company announced in a press release.

The National Psoriasis Foundation dedicated August to psoriasis education, awareness and education, designating it Psoriasis Action Month.

Tildrakizumab exhibited real-world efficacy and safety for long-term treatment of plaque psoriasis, according to a study.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a study published in JAMA Dermatology.